Avantor Faces Class Action for Misrepresentation; Investors May Claim Compensation
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 4 day ago0mins
- Legal Action Notice: Rosen Law Firm reminds investors who purchased Avantor (NYSE:AVTR) common stock between March 5, 2024, and October 28, 2025, to apply as lead plaintiffs by December 29, 2025, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Avantor misrepresented its competitive position and failed to disclose negative impacts from increased competition, resulting in investor losses when the true information was revealed, highlighting a significant discrepancy between the company's market performance and its public statements.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resources in handling such cases effectively.
- Investor Selection Advice: Investors are advised to choose counsel with a proven track record to ensure optimal representation in the class action, avoiding firms that merely act as intermediaries without substantial litigation experience.
AVTR.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 13.86 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.150
Low
12.00
Averages
13.86
High
17.00
Current: 11.150
Low
12.00
Averages
13.86
High
17.00
Raymond James
Outperform -> Market Perform
downgrade
2025-11-04
Reason
Raymond James
Price Target
2025-11-04
downgrade
Outperform -> Market Perform
Reason
Raymond James downgraded Avantor to Market Perform from Outperform without a price target. The company reported another "frustrating quarter" with a miss on sales, the analyst tells investors in a research note. The firm cites Avantor's reduced guidance and execution risks for the downgrade. Raymond James sees a lack of visibility to continue recommending the shares.
Barclays
Luke Sergott
Overweight -> Equal Weight
downgrade
$15 -> $12
2025-10-30
Reason
Barclays
Luke Sergott
Price Target
$15 -> $12
2025-10-30
downgrade
Overweight -> Equal Weight
Reason
As previously reported, Barclays analyst Luke Sergott downgraded Avantor to Equal Weight from Overweight with a price target of $12, down from $15. The company is not committing to earnings and sales growth next year given the early stages of its strategic review process, the analyst tells investors in a research note. Barclays awaits further details on Avantor's "revival" plan before again recommending the shares.
JPMorgan
Overweight -> Neutral
downgrade
$14 -> $12
2025-10-30
Reason
JPMorgan
Price Target
$14 -> $12
2025-10-30
downgrade
Overweight -> Neutral
Reason
JPMorgan downgraded Avantor to Neutral from Overweight with a price target of $12, down from $14. The company reported another "weak" quarter and its guide-down indicates limited turnaround visibility, the analyst tells investors in a research note. The firm finds it unclear when some of Avantor's "transitory and seemingly idiosyncratic" issues will subside, such as the operational headwinds impacting process chemicals.
Barclays
Luke Sergott
Overweight -> Equal Weight
downgrade
$15 -> $12
2025-10-30
Reason
Barclays
Luke Sergott
Price Target
$15 -> $12
2025-10-30
downgrade
Overweight -> Equal Weight
Reason
Barclays analyst Luke Sergott downgraded Avantor to Equal Weight from Overweight with a price target of $12, down from $15.
See All Ratings
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key allegations against Avantor in the class action lawsuits?
Why is Avantor's competitive positioning considered weaker than previously disclosed?
How might Avantor's stock price react if the lawsuits result in settlements?
What could happen to Avantor's market share if competition continues to increase?